RNF25 promotes gefitinib resistance in EGFR-mutant NSCLC cells by inducing NF-κB-mediated ERK reactivation

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Non-small cell lung cancer (NSCLC) patients with EGFR mutations often develop resistance to EGFR tyrosine kinase inhibitors (TKIs).
• Mechanisms of TKI resistance are not fully understood in a significant portion of NSCLC cases.
• Identifying novel resistance pathways is crucial for developing effective combination therapies.

Purpose of the Study:

• To investigate synthetic lethality with gefitinib in TKI-resistant EGFR-mutant NSCLC cells.
• To identify novel factors contributing to gefitinib resistance.
• To elucidate the molecular mechanisms underlying TKI resistance in NSCLC.

Main Methods:

• Genome-wide RNAi screening in TKI-resistant EGFR-mutant NSCLC cells.
• Assessment of RNF25 expression and its impact on gefitinib sensitivity.
• Analysis of NF-κB and ERK pathway activation in response to RNF25 modulation and gefitinib treatment.
• Investigation of cytokine involvement, including IL-6, in RNF25-mediated resistance.

Main Results:

• RNF25 was identified as a novel factor associated with gefitinib resistance in NSCLC.
• Depletion of RNF25 sensitized NSCLC cells to gefitinib, while its overexpression enhanced resistance.
• RNF25 mediates NF-κB activation, leading to ERK signal reactivation and drug resistance.
• ERK reactivation is mediated by cytokines like IL-6, induced by RNF25-NF-κB signaling.

Conclusions:

• RNF25 plays a critical role in gefitinib resistance in NSCLC by linking NF-κB and ERK pathways.
• RNF25 represents a potential therapeutic target for overcoming TKI resistance in NSCLC.
• Combination therapy targeting RNF25 could be a strategy to improve treatment outcomes for NSCLC patients.